Navigation Links
Siemens Introduces Life, an Open Fit Hearing Instrument That is Beautiful, Smart, and Discreet
Date:10/31/2008

Small and Light, yet Stylish and Sophisticated, Life is Full of Possibilities and Potent Technology for Wearers with Mild to Moderate Hearing Loss.

PISCATAWAY, N.J., Oct. 31 /PRNewswire-FirstCall/ --Personalizing solutions for those with hearing loss is a hallmark of Siemens Hearing Instruments, Inc., a leading manufacturer of hearing instruments. Now, Siemens follows through on this commitment by announcing their new Life hearing instruments at this year's International Congress of Hearing Aid Acousticians (EUHA) in Leipzig, Germany, from October 15-17, 2008. Life has been developed specifically for new and current users who live with style and want a hearing instrument that fits right in.

Smaller than most hearing instruments, light, sleek, and sophisticated, Life is easy for audiologists or hearing care providers to fit, with three performance levels to choose from in an open fitting configuration. Hassle-free, Life requires little maintenance thanks to its durable BTE style, ultra-thin LifeTubes, and replaceable tips. Life is also powerful with Siemens very latest natural-sound technologies, as well as fashionable with a palette of 16 exclusive colors and designs (with names such as Golden Blonde, Sandy Brown, Charming, Berry Charming, Fresh, and Suave).

Life hearing instruments are also capable of connecting to the wearer's personal world of sound in true stereo with Siemens Tek(TM), an optional wireless enhancement. Via Bluetooth(R) wireless technology, the Tek Transmitter streams sound from an MP3 player, mobile phone, TV, or other audio device to the Life hearing instruments, transforming them into a virtual wireless stereo headset. Not only are wearers impressed by Tek, but professionals are, as well.

"This product has been something that has absolutely excited me," said Kim O'Connell, hearing care professional at Micro Instruments, Inc., Montclair, New Jersey. "To be able to introduce something into someone's life, the yo
'/>"/>

SOURCE Siemens Healthcare
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Siemens Extends Tender Offer for Acquisition of Dade Behring
2. Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award
3. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
4. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
5. VIDEO from Medialink and Siemens: The Next Generation Allergy Test - Nothing to Sneeze At
6. Siemens Building Technologies Pioneers Wireless Solution for St. Anthonys Sensitive Environment
7. Susquehanna Health and Siemens Announce Plans to Improve Hospital Facilities Through Technology Investment
8. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
9. VIDEO from Medialink and Siemens: Worlds Smallest Ultrasound Package Launches in the U.S.
10. Siemens Soarian Health Information Management is Widely Adopted by Leading Healthcare Institutions in 2007
11. James Cracknell Launches Siemens Stroke for Stroke Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... Reporter , , TUESDAY, May 22 (HealthDay News) -- ... procedure, which involves threading a camera through the ... But a new study has found that patients ... less time-consuming CT-based colon scan. Colonoscopy ... colon cancer screening. Computed tomography (CT) colonography -- ...
(Date:5/23/2012)... in the United Kingdom have determined that azithromycin, ... can be an effective treatment option for patients ... complication that occurs in the majority of patients ... leading cause of mortality after the first year ... body repeatedly rejects the transplanted lung tissue. The ...
(Date:5/22/2012)... Children born with cleft lip, cleft palate and ... appearance. , Patients can face serious airway, feeding, ... and psychological challenges, Laura Swibel Rosenthal, MD, of ... the June 2012 issue of Otolaryngologic Clinics ... patients with craniofacial syndromes is complex," Rosenthal and ...
(Date:5/22/2012)... -- Researchers at Barrow Neurological Institute at St. ... and why the public perceives some magic tricks ... in military tactics, marketing and sports. , Susana ... and Stephen Macknik, PhD, of Barrow,s Laboratory of ... into magic and illusions. Their most recent original ...
(Date:5/22/2012)... (May 22, 2012) Scientists at Virginia Commonwealth ... closer to developing a new therapy for acute ... agents obatoclax and sorafenib kill leukemia cells much ... are administered individually., Recently published in the journal ... Steven Grant, M.D., Shirley Carter Olsson and Sture ...
Breaking Medicine News(10 mins):Health News:Patients Prefer More Invasive Form of Colon Scan: Study 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 3Health News:Study shows antibiotic improves respiratory function in lung transplant patients 2Health News:Cleft lip/palate cause much more than cosmetic problems 2Health News:Barrow researchers use magic for discoveries 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 3
... University have found that almost one in 10 Scottish ... of more than 2,000 students studying //in west-central Scotland ... between 13-16 demonstrated behaviors that could lead to gambling ... of 11-12 years, 6 percent of the children had ...
... his team has carried out research on a specific genetic ... one in a million births. “About 1,500 to 2,000 Americans ... says Dr. Pearson. According to him neonatal diabetes, when detected ... controlling the blood sugar levels more effectively. ,Tablets instead ...
... for a while due to its eradication, yet people could ... not been vaccinated says a recent report.// ... had spread after an unvaccinated teenager contracted the virus and ... gathering. This spurred a large outbreak in USA, which also ...
... Government of New Zealand has released a 10-year ‘action plan’ ... and addiction services. // ,It was reported that the ... and stated that the primary part of the work was ... have their needs attended to earlier by way of a ...
... an alarm clock that promises to wake its users up when ... Sleep Phase Alarm Clock checks 30 minutes before the alarm is ... or light phase of sleep, say the manufacturers Infacory Innovations, who ... recently in Munich. ,With the help of a sensor ...
... which is grown in many Indian homes, and pudina have ... University of Rajasthan.// ,"We arrived at our conclusions after ... heads the research project. ,"Our research came ... first divided into two groups and then applied with a ...
Other Medicine News:Health News:Painless Control Of Blood Sugar Levels When Detected Early 2
(Date:5/23/2012)... -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today ... U.S. phase 2 clinical trial, T reatment with ... reater E fficacy T rial (TARGET-NTM), ... with non-tuberculous mycobacterial (NTM) lung disease. ... current NTM treatment recommendations, and no new drugs have ...
(Date:5/23/2012)... TriReme Medical, Inc. (TMI) today announced approval by the ... PTCA Catheter, indicated for treating the stenotic portion of ... Glider™ is the world,s only torqueable PTCA ... tip technology, Glider™ is designed to perform, even in ... an ultra short balloon length of 4mm designed for ...
(Date:5/23/2012)... Reportlinker.com announces that a new ... catalogue: Pharmaceuticals - ... http://www.reportlinker.com/p0191857/Pharmaceuticals---Global-Group-of-Eight-G8-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu ... Industry Guide is an essential resource for ... industry in each of the G8 (United ...
Breaking Medicine Technology:Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 2Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 4Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 5TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter 2Pharmaceuticals - Global Group of Eight (G8) Industry Guide 2Pharmaceuticals - Global Group of Eight (G8) Industry Guide 3Pharmaceuticals - Global Group of Eight (G8) Industry Guide 4Pharmaceuticals - Global Group of Eight (G8) Industry Guide 5Pharmaceuticals - Global Group of Eight (G8) Industry Guide 6Pharmaceuticals - Global Group of Eight (G8) Industry Guide 7Pharmaceuticals - Global Group of Eight (G8) Industry Guide 8Pharmaceuticals - Global Group of Eight (G8) Industry Guide 9Pharmaceuticals - Global Group of Eight (G8) Industry Guide 10Pharmaceuticals - Global Group of Eight (G8) Industry Guide 11Pharmaceuticals - Global Group of Eight (G8) Industry Guide 12Pharmaceuticals - Global Group of Eight (G8) Industry Guide 13Pharmaceuticals - Global Group of Eight (G8) Industry Guide 14Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 1Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 2Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 3JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares 47583 1JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares 47583 2JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares 47583 3Streamline Health to Announce First Quarter Fiscal Year 2009 Financial Results on Tuesday June 9 2009 47582 1Streamline Health to Announce First Quarter Fiscal Year 2009 Financial Results on Tuesday June 9 2009 47582 2Streamline Health to Announce First Quarter Fiscal Year 2009 Financial Results on Tuesday June 9 2009 47582 3
... Results,published this week in The Lancet show that ... 6, 11,16, 18) Recombinant Vaccine) was 100 percent ... by HPV,types 16 and 18, two types strongly ... observed in women who were not,infected with HPV ...
... VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ ... for infectious,diseases will make a presentation of results ... study (see April 11, 2007,press release) in a ... being held in Washington, DC May 19-24,2007. Dr. ...
Other Medicine Technology:Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 29Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 30Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 31Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 32Migenix to Present Celgosivir Phase II Hepatitis C Results at,Digestive Disease Week 2007 2Migenix to Present Celgosivir Phase II Hepatitis C Results at,Digestive Disease Week 2007 3
9 inch sharp bone hook with grip handle....
Cleveland Bone Cutter #5, 17cm, 6-3/4"...
Beuse Zygomatic Arch Awl with slightly curved tip....
Steroid-eluting, single-pass lead. CapSure VDD2 optimizes VDD therapy and offers easier handling, proven performance, and choice....
Medicine Products: